Daily Oral Amycretin Study Abstract

[Dustycotton]

Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study

Results: At week 12, the mean change in body weight (amycretin 50 mg, -10.4% [SD, 4.6]; amycretin 2×50 mg, -13.1% [SD, 4.8]) was significantly greater with oral amycretin versus placebo (-1.1% [SD, 2.6]; p<0.0001 for both doses) (Fig. 1). The majority of AEs reported were mild to moderate in severity and related to gastrointestinal discomfort (i.e. nausea and vomiting), and decreased appetite. These AEs occurred in a dose-proportional manner, with low tolerability for dose levels ≥18 mg when amycretin was administered as a single dose and ≥12 mg when administered for 10 consecutive days. However, by introducing stepwise dose escalation, all tested dose levels up to and including 2×50 mg had acceptable safety and tolerability profiles.

 

[milos]

more info:

Amycretin is a novel protein-based unimolecular amylin combined with a glucagon-like peptide 1 receptor agonist (GLP-1 RA) and is the first oral formulation of this combination under development.

The two components are both known to reduce appetite and energy intake and increase satiety, said Gasiorek, but amylin is considered to potentially increase leptin sensitivity and GLP-1 RAs are known to increase insulin secretion and biosynthesis. Together, the two components improve insulin sensitivity, decrease glucagon secretion, and lead to acute delay in gastric emptying.

'Remarkable' Weight Loss With Novel Oral Combo in Phase 1

Amycretin, a dual pathway, oral weight loss drug, was found to be safe and tolerable in a phase 1 study and led to weight loss of up to 13% in people with overweight and obesity.

www.medscape.com

so basically something like CariSema but in a one compound